A 5-minute quiz might predict who gets severe chemo side effects
NCT ID NCT06717178
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy regimen. Researchers will then track hospitalizations, dose reductions, and treatment interruptions to see if the score matches real-world outcomes. The goal is to help doctors tailor chemotherapy plans to reduce harm in older adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Chemotherapy (a new chemotherapy regimen, either initial or changed)
- What this could lead to
- If the CARG score works well, it could help doctors predict which older patients are at higher risk of severe side effects, allowing safer, more personalized chemotherapy plans.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't change outcomes directly. The score may not predict accurately in Chinese patients, and results depend on how well patients report symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
360 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Academic medical centers
- Ages
-
70 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age≥ 70 years old * Confirmed diagnosis of solid tumor (any stage) * ECOG-PS score 0-2 points * Admission to the hospital for a new chemotherapy regimen (initial or change) * Patients need to have the ability to read and write, or communicate in Chinese * The patient must have the ability to give informed consent. Exclusion Criteria: * Patients who are on immunotherapy and/or targeted therapy only * Patients with hematologic malignancy * Patients with severe infections (sepsis, severe respiratory tract infections, severe urinary tract infections, severe abdominal infections, etc.). * Patients with severe heart, liver, and kidney dysfunction or failure
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Renji Hospital
Shanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?